SPS
TNXP icon

Susquehanna Portfolio Strategies’s Tonix Pharmaceuticals TNXP Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$830K Buy
+65,024
New +$839K 0.01% 584
2025
Q4 		– Sell
-41,454
Closed -$1M – 1129
2025
Q3 		$1M Hold
41,454
– – 0.02% 684
2025
Q2 		$1.49M Buy
+41,454
New +$1.09M 0.03% 430

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna Portfolio Strategies's TNXP Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 65,024 shares worth $830K. The stake represents 0.01% of the portfolio and ranks #584 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in TNXP as recently as Q3 2025.

Susquehanna Portfolio Strategies first reported a position in TNXP in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.49M in Q2 2025. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Susquehanna Portfolio Strategies held 65,024 shares of Tonix Pharmaceuticals worth $830K as of Q2 2026.
  • Tonix Pharmaceuticals was a new Susquehanna Portfolio Strategies position in Q2 2026.
  • Tonix Pharmaceuticals made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #584 holding.
  • Susquehanna Portfolio Strategies first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Susquehanna Portfolio Strategies's Tonix Pharmaceuticals position peaked at $1.49M in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.